Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Escitalopram and Depression in Elderly Alzheimer's Patients

This study has been terminated.
(Dr. Rabheru left VCH last year and the study was cancelled according to his research coordinator.)
Information provided by:
University of British Columbia Identifier:
First received: June 18, 2007
Last updated: June 2, 2011
Last verified: June 2011
To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

Condition Intervention Phase
Depressive Disorder
Drug: Escitalopram
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Change in Cornell Scale for Depression in Dementia (CSDD) from baseline. [ Time Frame: Unspecified ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study [ Time Frame: Unspecified ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: December 2010
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Escitalopram
    See Detailed Description.
Detailed Description:
This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • > 50 years
  • Male & female
  • Alzheimer's disease
  • Depressive episode
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00488670

Canada, British Columbia
Mt. St. Joseph's Hospital
Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Principal Investigator: Kiran Rabheru, MD University of British Columbia
  More Information

Responsible Party: Dr. Kiran Rabheru, University of British Columbia Identifier: NCT00488670     History of Changes
Other Study ID Numbers: H07-00050 
Study First Received: June 18, 2007
Last Updated: June 2, 2011
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
Alzheimer's disease

Additional relevant MeSH terms:
Alzheimer Disease
Depressive Disorder
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Mood Disorders
Behavioral Symptoms
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents processed this record on October 25, 2016